The toxicology of heparin reversal with protamine: past, present and future

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 8, 2016, Pages 897-909

  Sokolowska, Emilia ^a   Kalaska, Bartlomiej ^a   Miklosz, Joanna ^a   Mogielnicki, Andrzej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antidote; heparin; protamine; safety; toxicity

Indexed keywords

HEPARIN; ISOPHANE INSULIN; PROTAMINE; ANTICOAGULANT AGENT; ANTIDOTE; HEPARIN ANTAGONIST;

DRUG HYPERSENSITIVITY; HEART RIGHT VENTRICLE FAILURE; HEMOLYSIS; HUMAN; HYPOTENSION; LUNG TOXICITY; NEPHROTOXICITY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; THERAPEUTIC INDEX; TOXICOLOGY; VASCULAR SMOOTH MUSCLE; VASECTOMY; VASODILATATION; ANIMAL; CHEMICALLY INDUCED; DRUG DESIGN; HEMORRHAGE;

ANIMALS; ANTICOAGULANTS; ANTIDOTES; DRUG DESIGN; HEMORRHAGE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; PROTAMINES;

EID: 84979902977     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1194395     Document Type: Review

References (140)

1. J.Silvain, F.Beygui, O.Barthelemy, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.
2. M.Suranyi, J.S.Chow Review: anticoagulation for haemodialysis. Nephrology. 2010;15(4):386–392.
3. D.Mozzaffarian, E.J.Benjamin, A.S.Go, et al. Heart disease and stroke statistics-2015 update: a report from the American heart association. Circulation. 2015;131(4):e29–e322.
4. H.Kaneda, J.Suzuki, G.Hosokawa, et al. Impact of heparin neutralization by protamine on restenosis after coronary stent implantation. Int J Cardiol. 2005;105(1):111–112.
5. G.Lu, F.R.DeGuzman, S.J.Hollenbach, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–451.
6. J.Butterworth, Y.A.Lin, R.Prielipp, et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. 2002;94(3):514–522.• First-time reported protamine concentrations and pharmacokinetics in humans.
7. H.J.Ng, L.H.Lee. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag. 2006;2(4):433–434.
8. P.I.Johansson. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang. 2008;95(1):1–7.
9. J.Ansell, S.H.Bakhru, S.S.Laulicht, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2142.
10. B.Kalaska, E.Sokolowska, K.Kaminski, et al. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. Eur J Pharmacol. 2012;686(1–3):81–89.
11. B.Kalaska, K.Kaminski, E.Sokolowska, et al. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS One. 2015;10(3):e0119486.
12. E.Sokolowska, B.Kalaska, K.Kaminski, et al. The toxicokinetic profile of Dex40-GTMAC3 - a novel polysaccharide candidate for reversal of unfractionated heparin. Front Pharmacol. 2016;7:60.
13. R.A.Shenoi, M.T.Kalathottukaren, R.J.Travers, et al. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci Transl Med. 2014;6(260):260ra150.
14. B.Lorkowska-Zawicka, K.Kamiński, J.Ciejka, et al. Inactivation of heparin by cationically modified chitosan. Mar Drugs. 2014;12(7):3953–3969.
15. K.Kamiński, M.Plonka, J.Ciejka, et al. Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists. J Med Chem. 2011;54(19):6586–6596.
16. H.He, J.Ye, E.Liu, et al. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide. J Control Release. 2014;10(193):63–73.
17. S.M.Bromfield, E.Wilde, D.K.Smith. Heparin sensing and binding-taking supramolecular chemistry towards clinical applications. Chem Soc Rev. 2013;42(23):9184–9195.
18. J.C.Horrow. Protamine: a review of its toxicity. Anesth Analg. 1985;64(3):348–361.•• Predictable and idiosyncratic adverse responses to protamine administration in animals and humans.
19. R.Balhorn. The protamine family of sperm nuclear proteins. Genome Biol. 2007;8(9):227.1–227.8.
20. J.A.Carr, N.Silverman. The heparin-protamine interaction: a review. J Cardiovasc Surg. 1999;40(5):659–666.
21. J.Butterworth, Y.A.Lin, R.C.Prielipp, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74(5):1589–1595.
22. T.Mochizuki, P.J.Olson, F.Szlam, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87(4):781–785.
23. A.J.Chu, Z.G.Wang, M.Raicu, et al. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol. 2001;115(2):392–399.
24. F.Ni Ainle, R.J.S.Preston, P.V.Jenkins, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114(8):1658–1665.
25. K.G.Mann, M.Kalafatis. Factor V: a combination of Dr. Jekyll and Mr. Hyde. Blood. 2003;101(1):20–30.
26. V.G.Nielsen. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg. 2006;81(5):1720–1727.
27. M.J.Griffin, H.M.Rinder, B.R.Smith, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg. 2001;93(1):20–27.
28. M.Woltz, A.Weltermann, M.Nieszpaur-Los, et al. Studies on the neutralizing effect of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost. 1995;73(3):439–443.
29. M.A.Crowther, L.R.Berry, P.T.Monagle, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116(1):178–186.
30. D.Zhao, Q.Sang, H.Cui. Preparation and evaluation a new generation of low molecular weight heparin. Biomed Pharmacother. 2016;79:194–200.
31. A.DeLucia3rd, T.W.Wakefield, A.M.Kadell, et al. Tissue distribution, circulating half-life, and excretion of intravenously administered protamine sulfate. Asaio. 1993;39(3):M715–M18.•• Protamine (1) distributes particularly to the lungs, heart, and kidneys; (2) circulates beyond the time required to neutralize heparin anticoagulation; and (3) renal clearance seems to be enhanced in the presence of heparin.
32. K.G.Dougherty, C.M.Gaos, H.S.Bush, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn. 1992;26(4):260–263.
33. G.Whitman, D.Martel, M.Weiss, et al. Reversal of protamine-induced catastrophic pulmonary vasoconstriction by prostaglandin E1. Ann Thorac Surg. 1990;50(2):303–305.
34. Y.Q.Chu, L.J.Cai, D.C.Jiang, et al. Allergic shock and death associated with protamine administration in a diabetic patient. Clin Ther. 2010;32(10):1729–1732.
35. S.E.Kimmel, M.A.Sekeres, J.A.Berlin, et al. Risk factor for clinically important adverse events after protamine administration following cardiopulmonary bypass. Am J Coll Cardiol. 1998;32(7):1916–1922.
36. th edition). Chest. 2008;133(6Suppl):234S–256S.
37. J.D.Lakin, T.J.Blocker, D.M.Strong, et al. Anaphylaxis to protamine sulfate mediated by a complement-dependent IgG antibody. J Allergy Clin Immunol. 1978;61(2):102–107.
38. T.Horiguchi, K.Enzan, J.Matsumoto, et al. Marked systemic hypotension accopanied by pulmonary hypertension following protamine reversal of heparin: case report. J Anesth. 1994;8(4):503–505.
39. J.A.Marin-Neto, M.K.Sykes, J.L.Marin, et al. Effect of heparin and protamine on left ventricular performance in the dog. Cardiovasc Res. 1979;13(5):254–259.
40. T.W.Wakefield, D.B.Hinshaw, J.M.Burger, et al. Protamine-induced reduction of endothelial cell ATP. Surgery. 1989;106(2):378–385.
41. J.T.Knape, J.L.Schuller, P.De Haan, et al. An anaphylactic reaction to protamine in a patient allergic to fish. Aneasthesiology. 1981;55(3):324–325.
42. W.J.Stewart, S.M.McSweeney, M.A.Kellett, et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation. 1984;70(5):788–792.• Patient receiving NPH insulin have a 50-fold increased risk of an unexpected reaction to protamine.
43. U.Adourian, E.L.Shampaine, C.A.Hirshman, et al. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology. 1993;78(2):368–372.
44. J.H.Levy, I.M.Schweiger, J.R.Zaidan, et al. Evaluation of patients at risk for protamine reactions. J Throac Cardiovasc Surg. 1989;98(2):200–204.• Prior NPH insulin use, a history of fish allergy, or a prior vasectomy are not a contraindication to protamine administration after CPB.
45. J.C.Brooks. Noncardiogenic pulmonary edema immediately following rapid protamine administration. Ann Pharmacother. 1999;33(9):927–930.
46. E.Lowenstein, W.E.Johnston, D.G.Lappas, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology. 1983;59(5):470–473.
47. T.W.Wakefield, B.Lindblad, T.J.Stanley, et al. Heparin and protamine use in peripheral vascular surgery: a comparison between surgeons of the society for vascular surgery and the European society for vascular surgery. Eur J Vasc Surg. 1994;8(2):193–198.
48. H.A.Seifert, D.R.Jobes, H.T.Ten, et al. Adverse events after protamine administration following cardiopulmonary bypass in infants and children. Anesth Analg. 2003;97(2):383–389.
49. I.J.Welsby, M.F.Newman, B.Phillips-Bute, et al. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology. 2005;102(2):308–314.
50. J.M.Weiler, M.A.Gellhaus, J.G.Carter, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990;85(4):713–719.
51. M.Nybo, J.S.Madsen. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103(2):192–196.•• Incidence of anaphylactic reactions to protamine is in the range of 0.19–0.69%.
52. J.Levy, J.R.Zaidan, B.Faraj. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg. 1986;65(7):739–742.
53. A.Fowler, M.Baird, D.Eberle, et al. Attack rates and mortality of the adult respiratory distress syndrome in patients with known predispositions. Am Rev Respir Dis. 1983;125(4):77.
54. S.Hashim, H.Kay, G.Hammond, et al. Noncardiogenic pulmonary edema after cardiopulmonary bypass: an anaphylactic reaction to fresh frozen plasma. Am J Surg. 1984;147(4):560–564.
55. N.Shapira, H.V.Schaff, J.M.Piehler, et al. Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg. 1982;84(4):505–514.• Protamine-induced hypotension is primarily the result of peripheral vasodilatation.
56. M.A.Fadali, M.Ledbetter, C.A.Papacostas, et al. Mechanism responsible for the cardiovascular depressant effect of protamine sulfate. Ann Surg. 1974;180(2):232–235.
57. N.M.Katz, Y.D.Kim, R.Siegelman, et al. Hemodynamics of protamine administration. Comparison of right atrial, left atrial, and aortic injections. J Thorac Cardiovasc Surg. 1987;94(6):881–886.
58. D.Pevni, J.Gurevich, I.Frolkis, et al. Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway. Ann Thorac Surg. 2000;70(6):2050–2053.• Heparin does not prevent the relaxing effect of protamine.
59. R.L.Hines, P.G.Barash. Protamine does it alter right ventricular function? Anesth Analg. 1986;65(12):1271–1274.
60. T.W.Wakefield, I.Ucios, T.F.Kresowik, et al. Decreased oxygen consumption as a toxic manifestation of protamine sulfate reversal of heparin anticoagulation. J Vasc Surg. 1989;9(6):772–777.
61. P.J.Pearson, P.R.Evora, K.Ayrancioglu, et al. Protamine releases endothelium-derived relaxing factor from systemic arteries. A possible mechanism of hypotension during heparin neutralization. Circulation. 1992;86(1):289–294.•• Protamine induces the release of NO/EDRF from endothelium and causes endothelium-dependent vasodilation, which is a reason for systemic hypotension after protamine administration.
62. T.Uruno, R.Matsumoto, K.Okushita, et al. Possible mechanisms of inhibitory actions of protamine on contractile activity of rat aorta. J Pharm Pharmacol. 1985;37(7):476–480.
63. L.J.Ignarro, M.E.Gold, G.M.Buga, et al. Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein. Circ Res. 1989;64(2):315–329.
64. J.C.Horrow. Protamine allergy. J Cardiothorac Anesth. 1988;2(2):225–242.
65. M.Friedman, R.G.Johnson, S.Y.Wang, et al. Pulmonary microvascular responses to protamine and histamine. Effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;108(6):1092–1099.
66. A.Baraka, P.Choueiry, S.Taha, et al. Hydrocortisone pretreatment for attenuation of protamine induced adverse hemodynamic reactions. J Cardiothorac Vasc Anesth. 1995;9(4):481–482.
67. M.Behne, D.Bremerich, S.Schiesser, et al. Efficiency of hypotension prophylaxis with H1/H2 receptor antagonists before protamine administration. Infus Ther Transfusionsmed. 1994;21(2):81–85.
68. M.Pretorius, F.G.Scholl, J.A.McFarlane, et al. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther. 2005;78(5):477–485.
69. W.Buczko, K.Kramkowski, A.Mogielnicki. Are the endothelial mechanisms of ACE-Is already established? Pharmacol Rep. 2006;58Suppl:126–131.
70. R.M.Palmer, D.D.Rees, D.S.Ashton, et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153(3):1251–1256.
71. S.Moncada, A.E.Higgs. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest. 1991;21(4):361–374.
72. D.Cylwik, A.Mogielnicki, W.Buczko. L-arginine and cardiovascular system. Pharmacol Rep. 2005;57(1):14–22.
73. D.Cylwik, A.Mogielnicki, K.Kramkowski, et al. Antithrombotic effect of L-arginine in hypertensive rats. J Physiol Pharmacol. 2004;55(3):563–574.
74. T.Nakaki, K.Hishikawa, H.Suzuki, et al. L-arginine induced hypotension. Lancet. 1990;336(8716):696.
75. P.R.B.Evora, P.J.Pearson, H.V.Schaff. Protamine induces endothelium dependent vasodilatation of the pulmonary artery. Ann Thorac Surg. 1995;60(2):405–410.•• Protamine-induced pulmonary vasodilatation could be a potential mechanism protecting against the constrictive effects of autocoids generated after protamine administration. Dysfunction of the mechanism in certain persons can change the vasodilator properties of protamine to vasoconstrictive.
76. W.K.Alderton, C.E.Cooper, R.G.Knowles. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357(Pt 3):593–615.
77. Y.Hayashi, Y.Sawa, N.Fukuyama, et al. Inducible nitric oxide production is an adaptation to cardiopulmonary bypass-induced inflammatory response. Ann Thorac Surg. 2001;72(1):149–155.
78. S.Moncada, R.M.Palmer, E.A.Higgs. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109–142.
79. G.Ruvolo, E.Greco, G.Speziale, et al. Nitric oxide formation during cardiopulmonary bypass. Ann Thorac Surg. 1994;57(4):1055–1057.
80. S.Wan, J.M.DeSmet, L.Barvais, et al. Myocardium is major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996;112(3):806–811.
81. K.Takakura, M.Mizogami, S.Fukuda. Protamine sulfate causes endothelium-independent vasorelaxation via inducible nitric oxide synthase pathway. Can J Anesth. 2006;53(2):162–167.
82. T.Akata, K.Kodama, J.Yoshite, et al. Heparin prevents the vasodilatating action of protamine on human small mesenteric arteries. Anesth Analg. 1993;76(6):1213–1221.
83. Z.Orescanin-Dusic, S.Milovanovic, M.B.Spasic, et al. Effect of protamine sulfate on the isolated mesenteric arteries of normotensive and a spontaneously hypertensive rats. Arch Biol Sci. 2008;60(2):163–168.•• Opposite vascular endothelium, the vascular smooth muscle plays a significant role in protamine-induced relaxation.
84. K.Murase, K.Naruse, A.Kimura, et al. Protamine augments stretch induced calcium increase in vascular endothelium. Br J Pharmacol. 2001;134(7):1403–1410.
85. Z.Orescanin-Dusic, S.Milovanovic, R.Radojicic, et al. Effects of protamine sulphate on spontaneous and calcium-induced contractile activity in the rat uterus are potassium channels-mediated. Gen Physiol Biophys. 2009;28(SpecNo):143–148.
86. I.Golbasi, C.Nacitarhan, S.Ozdem, et al. The inhibitory action of protamine on human internal thoracic artery contractions: the effect of free hemoglobin. Eur J Cardiothorac Surg. 2003;23(6):962–968.
87. J.Appiah, S.Milovanovic, R.Radojicic, et al. Hydrogen peroxide affects contractile activity and antioxidant enzymes in rat uterus. Br J Pharmacol. 2009;158(8):1932–1941.
88. J.S.David, B.Vivien, Y.Lecarpentier, et al. Interaction of protamine with alpha- and beta-adrenoceptor stimulations in rat myocardium. Anesthesiology. 2001;95(5):1226–1233.
89. R.B.Hird, F.A.Crawford, R.Mukherjee, et al. Effect of protamine on myocyte contractile function and β adrenergic responsiveness. Ann Thorac Surg. 1994;57(5):1066–1075.
90. M.K.Pugsley, V.Kalra, S.Froebel-Wilson. Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle. Life Sci. 2002;72(3):293–305.
91. S.L.Chudasama, B.Espinasse, F.Hwang, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood. 2010;116(26):6046–6053.
92. K.M.Gurses, D.Kocyigit, M.U.Yalcin, et al. Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. J Interv Card Electrophysiol. 2015;43(2):161–167.
93. K.Chilukuri, C.A.Henrikson, D.Dalal, et al. Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;25(3):175–181.
94. T.Bakchoul, H.Zöllner, J.Amiral, et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood. 2013;121(15):2821–2827.
95. G.M.Lee, I.J.Welsby, B.Phillips-Bute, et al. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood. 2013;121(15):2828–2835.
96. P.Grieshaber, T.Bakchoul, J.Wilhelm, et al. Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2015;150(4):967–973.
97. S.Panzer, A.Schiferer, B.Steinlechner, et al. Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis. Clin Chem Lab Med. 2015;53(2):249–255.
98. D.R.Morel, W.M.Zapol, S.J.Thomas, et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology. 1987;66(5):597–604.
99. A.Ocal, I.Kiris, M.Erdinc, et al. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med. 2005;207(1):51–58.
100. J.Jastrzebski, M.K.Sykes, D.G.Woods. Cardiorespiratory effects of protamine sulfate in man. Thorax. 1974;29(5):534–538.
101. P.G.Laubser. Effect of methylprednisolone on complement activation during heparin neutralization. J Cardiovasc Pharmacol. 1997;29(1):23–27.
102. R.P.Fairman, C.N.Sessler, M.Bierman, et al. Protamine sulfate causes pulmonary hypertension and edema in isolated rat lungs. J Appl Physiol. 1987;62(4):1363–1367.
103. D.R.Morel, D.Lowenstein, T.Nguyenduy, et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Circ Res. 1988;62(5):905–915.
104. P.F.Conzen, H.Habazettl, R.Gutmann, et al. Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs. Anesth Analg. 1989;68(1):25–31.
105. R.D.Deggers, M.E.Foster, A.Q.Dang, et al. Pulmonary hypertensive effect of heparin and protamine interaction: evidence for thromboxane B2 release from the lung. Am J Surg. 1987;154(6):696–699.
106. P.J.Pearson, H.V.Schaff, P.M.Vanhoutte. Long-term impairment of endothelium-dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation. 1990;81(6):1921–1927.
107. G.M.B.Berger, P.R.Abraham. Selective protamine sulphate inactivation of lipoprotein lipase and hepatic lipase in human postheparin plasma: specific lipase levels in normals and in type I hyperlipoproteinaemia. Clin Chim Acta. 1977;81(3):219–228.
108. J.L.Harwood, S.E.Riley, D.S.Robinso. The action of protamine on clearing factor lipase and plasma triglyceride metabolism. Biochem Biophys Acta- Lipids and Lipid Metabolism. 1974;337(2):225–238.
109. T.Saito, E.Sumithran, E.F.Glasgow, et al. The enhancement of aminonucleoside nephrosis by co-administration of protamine. Kidney Int. 1987;32(5):691–699.
110. V.M.Vehaskari, E.R.Root, F.G.GermuthJr, et al. Glomerular charge and urinary protein excretion: effects of systemic and intrarenal polycation infusion in the rat. Kidney Int. 1982;22(2):127–135.
111. A.Messina, D.J.Davies, G.B.Ryan. Protamine sulphate-induced proteinuria: the roles of glomerular injury and depletion of polyanion. J Pathol. 1989;158(2):147–156.
112. S.G.Adler, H.Wang, H.J.Ward, et al. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest. 1983;71(3):487–499.
113. A.R.Koslow, D.O.DeFouw, M.D.Farad, et al. Protamine-induced pulmonary edema in rats. Curr Surg. 1987;44(3):219–224.
114. J.J.Cook, S.Niewiarowski, Z.Yan, et al. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation. 1992;85(3):1102–1109.
115. S.W.Chang, N.F.Voelkel. Charge-related lung microvascular injury. Am Rev Respir Dis. 1989;139(2):534–545.
116. C.S.P.Jenkins, M.A.Packham, R.L.Kinlough-Rathbone, et al. Interactions of polylysine with platelets. Blood. 1971;37(4):395–412.
117. C.Eika. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 1972;9(3):248–257.
118. A.Olsson, J.Alfredsson, E.Hakansson, et al. Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass. Scand Cardiovasc J. 2016;50(1):58–63.
119. J.H.Schulman, B.A.Pethica, A.V.Few, et al. The physical chemistry of haemolysis and bacteriolysis by surface active agents and antibiotics. Progr Biophys. 1955;5:41–71.
120. F.F.Becker. Studies on the hemolytic properties of protamine. J Gen Physiol. 1961;44:433–442.
121. H.T.Ransdell, J.A.HallerJr, D.Stowens, et al. Renal toxicity of polybrene (hexadimethrine bromide). J Surg Res. 1965;5:195–199.
122. F.Jacobsen, T.Hirsch, D.Mittler, et al. Polybrene improves transfection efficacy of recombinant replication-deficient adenovirus in cutaneous cells and burned skin. J Gene Med. 2006;8(2):138–146.
123. B.J.Kim, K.J.Kim, Y.H.Kim, et al. Efficient enhancement of lentiviral transduction efficiency in murine spermatogonial stem cells. Mol Cells. 2012;33(5):449–455.
124. C.Zhao, N.Wu, F.Deng, et al. Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene. PLoS One. 2014;9(3):e92908.
125. J.G.Kelton, J.W.Smith, T.E.Warkentin, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83(11):3232–3239.
126. J.H.Levy, J.G.Cormack, A.Morales. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg. 1995;81(1):35–37.
127. L.Demma, J.H.Levy. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg. 2012;115(6):1273–1278.
128. S.B.Rosenfeld, K.K.Watkinson, B.H.Thompson, et al. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost. 2002;87(5):925–926.
129. R.d’Oiron, C.Menart, M.C.Trzeciak, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83(5):644–647.
130. K.Peerlinck, J.Vermylen. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82(6):1775–1776.
131. M.Levi, J.H.Levy, H.F.Andersen, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791–1800.
132. C.E.Mahan. A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents. J Thromb Thrombolysis. 2014;37(3):271–278.
133. D.J.Cushing, W.D.Cooper, M.L.Cohen, et al. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. Eur J Pharmacol. 2010;635(1–3):165–170.
134. A.J.Gale, D.J.Elias, P.M.Averell, et al. Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients. Thromb Res. 2011;128(4):e9–e13.
135. A.M.Lincoff, R.Mehran, T.J.Povsic, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387(10016):349–356.
136. C.V.Pollack, P.A.Reilly, J.Eikelboom, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520.
137. B.Kalaska, K.Kaminski, E.Sokolowska, et al. Novel synthetic copolymers able to bind unfractionated and low molecular weight heparins. ISTH 2015 Congress; 2015 Jun20–25; Toronto. 13(Suppl 2): 371(abstract).
138. M.Crowther, M.Kitt, T.Lorenz, et al. A phase 2 randomized, double blind placebo controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013;11(Suppl2):AS20.1. Abstract no. 3636.
139. F.Ö.Davidsson, D.Johagen, M.Appelblad, et al. Reversal of heparin after cardiac surgery: protamine titration using a statistical model. J Cardiothorac Vasc Anesth. 2015;29(3):710–714.
140. A.Bouraghda, P.Gillois, P.Albaladejo. Alternatives to heparin and protamine anticoagulation for cardiopulmonary bypass in cardiac surgery. Can J Anaesth. 2015;62(5):518–528.